From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Diagnostic and Economic Value of Biomarker Testing for Targetable Mutations in Non-Small-Cell Lung Cancer: A Literature Review

This study aimed to assess the diagnostic and economic value of next-generation sequencing (NGS) versus single-gene testing, and of liquid biopsy (LBx) versus tissue biopsy (TBx) in non-small-cell lung cancer biomarker testing through literature review. Turnaround times were longer for NGS versus single-gene testing (but not vs sequential testing) and faster for LBx versus TBx. NGS was cost-effective, and LBx reduced US per-patient costs. NGS versus single-gene testing and LBx versus TBx were concordant. NGS and LBx may be cost-effective for initial screening.

Future Medicine
Advertisement
News & Literature Highlights
Advertisement
Advertisement